ClinicalTrials.gg

Kidney Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 969 studies for Kidney Neoplasms across more than 10 countries. 209 are recruiting or about to start. 279 of them are mainly about Kidney Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 3 narrower conditions too, such as Carcinoma, Renal Cell: 2,695 studies, 558 open.

ClinicalTrials.gov finds 3,348 studies for Kidney Neoplasms. How that becomes 968 here

This page counts the studies the registry files under Kidney Neoplasms, and those it files under no condition that list Kidney Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 3,348Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,662Filed under a narrower condition, counted on its own pageCarcinoma, Renal Cell 1,482 · Wilms Tumor 143 · Clear-cell metastatic renal cell carcinoma 10
  3. −5List Kidney Neoplasms as a condition, but the registry did not file them under itMost often written as “Recurrent Childhood Kidney Neoplasm” (1), “Childhood Kidney Neoplasm” (1), and “Clear Cell Renal Cancer” (1). The registry filed them under other conditions only, most often Hepatoblastoma (1) and Precursor Cell Lymphoblastic Leukemia-Lymphoma (1).
  4. −713Match it another way11 name it in the title, 5 in a keyword, and 697 by a synonym or other text the search reads.
  5. 968The count on this page11 of them list Kidney Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
471
Recruiting
172
Terminated
113
Status unknown
81
Active, not recruiting
59
Withdrawn
33

Phase

Phase 2
345
Phase 1
229
Phase 3
57
Phase 4
21
Early Phase 1
9

Where

United States
551
France
108
China
68
United Kingdom
66
Canada
62
Italy
57

Who develops what

Add Kidney Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 19 programs from 14 companies, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Beijing Biotech, AstraZeneca and Arcus Biosciences here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
IpilimumabRecent, repeated
Evidence
  • NCT07227415 · Pfizer · Phase 2 · live · background · “Ipilimumab” · registered Nov 2025
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)22 studies

8 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 19 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 1 Jan 2027 est.SL-28 · Second Life Therapeutics · Phase 2 named, not the main aimNCT07341737 SL-28 for Advanced Solid Tumours — primary endpoint: Number of participants with treatment-emergent adverse events · 60 enrolled
  • 30 Mar 2027 est.Psilocybin · psyence australia pty ltd · Phase 2 named, not the main aimNCT07072728 Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder — primary endpoint: Anxiety Severity · 87 enrolled
  • 14 Apr 2027 est.eb-701, EB-701/CA9-NK, fludarabine · Beijing Biotech · Phase 2 named, not the main aimNCT07551349 Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma — primary endpoint: Incidence of dose-limiting toxicities (DLTs) · 36 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Kidney Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 13 open · Tyrosine kinase inhibitors (TKIs) 11 open · Antimetabolites 2 open · Alkylating agents 2 open · Angiogenesis inhibitors 1 open

Coming up

82studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 172 Kidney Neoplasms studies recruiting now, 132 (77%) set no upper age limit and 15 (9%) stop at 75 or younger. 20 (12%) take children under 18. 1 (1%) are for women only and 2 (1%) for men only; 24 (14%) take healthy volunteers.

Recruiting studies that take each age, of 172
AgeWomenMen
1018 (10%)18 (10%)
18161 (94%)162 (94%)
30164 (95%)165 (96%)
40165 (96%)166 (97%)
50166 (97%)167 (97%)
65168 (98%)169 (98%)
75164 (95%)165 (96%)
85142 (83%)143 (83%)

Across all 969 studies, recruiting or not: 11% stop at 75 or younger and 5% at 65; 14% take children; <1% are for women only and 1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Kidney Neoplasms studies take

Of 74 phase 2 interventional studies under Kidney Neoplasms, half reached primary completion within 67 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 156 mo33–75 · 65 studies53 mo28–61 · 42 studies—
Phase 1/266 mo61–91 · 31 studies——
Phase 267 mo36–112 · 74 studies—67 mo41–112 · 64 studies
Phase 370 mo35–89 · 22 studies——
Interventional, no phase42 mo21–90 · 97 studies—48 mo24–94 · 90 studies
Observational74 mo28–… · 107 studies—74 mo34–… · 89 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 969. Browse all 969 → or search them.